Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Dimethylitaconate" patented technology

Use of dimethyl itaconate in the prevention and treatment of chronic stress-induced anxiety

PendingCN122251384AOrganic active ingredientsNervous disorderLysosomeMitochondrial structure
The application provides application of dimethyl itaconate in prevention and treatment of chronic stress-induced anxiety. The application finds that dimethyl itaconate can inhibit excessive activation of microglial cells in a stress state, improve mitochondrial structure and function abnormalities of the microglial cells, and reduce expression of a lysosome marker CD68, so as to inhibit central nervous inflammation, maintain central nervous immune homeostasis, prevent and relieve anxiety-like behavior induced by chronic stress, and effectively prevent and relieve occurrence and development of chronic stress-induced anxiety (generalized anxiety disorder).
Owner:GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)

Application of itaconic acid derivatives in the preparation of drugs for treating candidemia

PendingCN122272557AReduce pathological damageReduce fungal colonizationInflammatory factorsTherapeutic effect
This application discloses the use of itaconic acid derivatives in the preparation of drugs for treating candidemia, belonging to the field of biomedical technology. The itaconic acid derivatives proposed in this application are dimethyl itaconic acid and / or 4-octyl itaconic acid. Dimethyl itaconic acid exhibits a dose-dependent therapeutic effect in model mice, with an optimal dose of 1200 mg / kg improving survival rate and reducing kidney damage; 4-octyl itaconic acid can enhance the anti-Candida albicans ability of macrophages and regulate the expression of inflammatory factors. The application of the itaconic acid derivatives proposed in this application in the treatment of candidemia works through immunomodulation, circumventing fungal resistance. Furthermore, the drugs are low in toxicity, have good biocompatibility, and use a universal experimental system, providing a new approach for the clinical treatment of candidemia with broad application prospects. This application also protects pharmaceutical compositions for treating candidemia with dimethyl itaconic acid and / or 4-octyl itaconic acid as active ingredients.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Process for the preparation of bio-based non-isocyanate polycaprolactam ureas

The preparation method of bio-based non-isocyanate polyitaconamide urea belongs to the field of polymer synthesis and bio-based green materials. First, dimethyl itaconate is used to react with excess aliphatic diamine through Michael addition and intramolecular cyclization melt polycondensation, a rigid pyrrolidone heterocycle is introduced in situ in the main chain, and an amino-terminated itaconic acid polyamide prepolymer is formed. Subsequently, ethylene carbonate is used as a chain extender to carry out green bulk polymerization process without solvent and catalyst, and a strong hydrogen bonding non-isocyanate urea bond network is efficiently constructed. The present application ingeniously constructs a ternary synergistic system of "rigid heterocycle-strong hydrogen bond-long and short aliphatic chain", and the obtained material has excellent and comprehensive balanced performance.
Owner:BEIJING UNIV OF CHEM TECH